Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Seattle Genetics (SGEN) PT Raised to $77 at H.C. Wainwright
February 7, 2018 7:24 AM ESTH.C. Wainwright raised its price target on Seattle Genetics (NASDAQ: SGEN) to $77.00 (from $75.00) while maintaining a Buy rating.
Analyst Andrew Fein commented, "Beyond ADCETRISs continuous label expansion/revenue growth and the companys ADC platform milestone generation, we see the solid tumor pipeline as the most interesting value driver with three late-stage programs that could expand SGENs footprint beyond hematology. The recent acquisition of Cascadian Therapeutics (CASC; not rated) and its HER2+ breast cancer... More
Seattle Genetics (SGEN) PT Raised to $60 at SunTrust Robinson Humphrey
February 7, 2018 7:10 AM ESTSunTrust Robinson Humphrey raised its price target on Seattle Genetics (NASDAQ: SGEN) to $60.00 (from $52.00) while maintaining a Hold rating.
Analyst Suneja Yatin commented, "SGEN reported a slight (+3%) beat in Adcetris 4Q sales, while LPS also topped Street (-$0.41 vs. -$0.45E) on... More
